Viewing Study NCT00386802



Ignite Creation Date: 2024-05-05 @ 5:05 PM
Last Modification Date: 2024-10-26 @ 9:28 AM
Study NCT ID: NCT00386802
Status: COMPLETED
Last Update Posted: 2009-09-18
First Post: 2006-10-11

Brief Title: Antifungal Use in Oncohematological Neutropenic Patients
Sponsor: PETHEMA Foundation
Organization: PETHEMA Foundation

Study Overview

Official Title: ANTIVORIFUNGOLStrategy of Antifungal Use in Oncohematological Neutropenic Patients Use of Voriconazole as Early Treatment
Status: COMPLETED
Status Verified Date: 2009-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Primary purpose Frequency of use of broad-spectrum antifungals in the episode of neutropenia

Secondary purposesTo determine the safety and toxicity measure by

1 Frequency of Invader Fungal Infection
2 Frequency of global use of broad-spectrum antifungals as amphotericine itraconazole voriconazole caspofungin terbinafine during the period of study
3 Mortality
4 Development of nephrotoxicity
5 Use of galactomannan in this clinical context
6 Time of administration of empirical antifungal therapy of broad-spectrum
Detailed Description: Clinical trial with a pharmaceutical speciality in the conditions of authorized use

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
ANTIVORIFUNGOL None None None